Is Baekje Shenzhou a state-owned enterprise or a foreign enterprise?

Baekje Shenzhou is not a state-owned enterprise, but a commercial biotechnology company, belonging to a foreign-funded enterprise. Baekje Shenzhou refers to Baekje Shenzhou Co., Ltd. Since its establishment, it has always adhered to the concept of "taking patients as the center and taking science and quality as the purpose", focusing on the research, development, production and commercialization of innovative drugs. Through continuous improvement of R&D and innovation capabilities, and cooperation with international pharmaceutical companies, the company has approved a number of products to go on the market and launched business in many countries and regions around the world.

Product development and listing

Baekje Shenzhou has made great achievements in product research and development. At present, three products of the company have been approved for listing, namely Bai Yueze (BGB-311), Bai Ze An (BGB-A3 17) and Bai Huize (BGB-290). In addition, there are eight products in the clinical stage, covering a variety of indications in the field of treatment. The research, development and listing of these products have fully demonstrated the innovative strength and technical level of Baekje Shenzhou in the field of biomedicine.

Globalization layout and development

Baekje Shenzhou's business covers many countries and regions around the world, including China, the United States, Australia, Canada, Singapore, Russia, Brazil and Europe. The company has established a wide range of sales networks and partnerships around the world, providing strong support for the marketing and sales of products. At the same time, Baekje Shenzhou has also actively expanded international cooperation, established strategic cooperative relations with many internationally renowned pharmaceutical companies, and promoted the R&D and commercialization of innovative drugs.

Corporate culture and values

Baekje Shenzhou attaches great importance to the construction of corporate culture and values. The mission of the company is to establish a new generation of global biotechnology enterprises, with innovation and challenging the status quo as the core driving force, so that high-quality treatment programs can benefit billions of people around the world. The company's vision is to become a revolutionary in the biotechnology industry and provide effective, accessible and affordable drugs for cancer patients all over the world. On this basis, Baekje Shenzhou has formed the values of "patient first, innovation, unbounded cooperation and pursuit of Excellence" and the code of conduct of "the process of doing things is as important as the result".

Market performance and prospects

Baekje Shenzhou has made great achievements in market performance, and its operating income and product sales have continued to grow. At the same time, the company is also increasing investment in research and development to promote the research and development process of innovative drugs. Looking forward to the future, with the continuous expansion of the global biomedical market and the increasing demand of patients for high-quality treatment programs, Baekje Shenzhou is expected to continue to maintain a strong growth momentum. The company will continue to adhere to the concept of innovation, quality and patient first, and provide more and better treatment programs for patients around the world.